Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
MedImmune Inc
MedImmune Inc
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Media
Merck is set to lead pharmaceutical licensing deals in 2018
GlobalData, a specialist data and analytics company, expects that 2018 is likely to be Merck’s year in terms of research and development collaboration
Research & Development
MedImmune and Abpro enter into a collaborative agreement for a novel bispecific antibody
Agreement to result in new spin out company, AbMed, as subsidiary of Abpro
Research & Development
AstraZeneca launches integrated genomics approach to transform drug discovery and development
The initiative includes new collaborations with Human Longevity, the Wellcome Trust Sanger Institute and The Institute for Molecular Medicine
Research & Development
AstraZeneca and Moderna Therapeutics link up to develop immuno-oncology mRNA therapeutics
Extension to an mRNA agreement for cardiovascular, metabolic and renal diseases set up in 2013
Manufacturing
Wacker Biotech grants MedImmune licence to use Esetec technology to manufacture antibody fragment
To help improve productivity and simplify the purification process
Research & Development
AstraZeneca signs third cancer deal in seven days
MedImmune enters into cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals
Research & Development
Medimmune partners with the University of Sheffield to innovate cell factory technology
Partnership will create tools that could increase the yield and predictability of engineered proteins such as bispecific antibodies to treat a range of diseases
Subscribe now